Biomet Biologics

Biomet Biologics

Mission

Biomet's foremost obligation is to the patient. Biomet works in concert with health professionals throughout the world to provide high quality and clinically proven medical products. Founded in 1977, Biomet has over 35 years of clinical heritage.

History

Biomet Biologics was formed in 2001 and launched its original platelet concentration device, the GPS Platelet Concentration System, in 2003. The proprietary buoy system from the GPS device provided the foundation to further expand our product offering, creating novel products such as the Plasmax Plasma Concentration System, the Clotaylst Autologous Activation Solution and the BioCUE Platelet Concentration System.

Furthermore, demineralized bone matrix (DBM) materials were added to the product portfolio to provide a complimentary allograft delivery mechanism for existing autologous therapies. Biomet Biologics has one of the broadest product lines in the industry and continues to be a market leader for autologous therapy products.

Biomet Biologics continues to support and invest in product development and clinical trials for a variety of therapeutic applications, including blood management, bone grafting, and vascular therapies. One such example is the ongoing MarrowStim PAD clinical trial, which involves stem cell therapy for critical limb ischemia, a specific type of vascular disease.

2001
Biomet Biologics Initiated
2003
GPS Released
2004
Bonus DBM GPS II Released
2005
GPS II with Plasmax Released
2006
IDE Initiated for PRP in Tennis Elbow MarrowStim/ BioCUE GPS III Released
2008
Clotalyst with GPS III Released
2010
Acquire Cytosol IDE initiated for MarrowStim PAD/CLI
2011
DermaSpan ACD Released
2013+
Additional Clinical Trials Planned